viewSareum Holdings PLC

Sareum's Tim Mitchell upbeat after 'very successful' early-stage cancer trial

Sareum Holdings PLC (LON:SAR) chief executive Tim Mitchell caught up with Proactive London's Andrew Scott to discuss some preliminary efficacy data released on a drug that Sareum helped to develop.

Of particular note was the impact SRA737 had in combination with a common chemotherapy called gemcitabine in patients with anogenital cancer ... ''the trial's been very, very successful indeed'', Mitchell says.

The data's been taken from a phase I/II clinical trial undertaken by Sierra Oncology, which licensed the drug candidate in a deal worth up to US$328.5mln plus royalties.

Quick facts: Sareum Holdings PLC

Price: 0.895 GBX

Market: AIM
Market Cap: £29.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...



Sareum Holdings says Phase I clinical trials for CHK1 could potentially...

Tim Mitchell, chief executive officer at cancer drug discovery company Sareum Holdings (LON:SAR), talks to Proactive Investors about the progress achieved by all of its programmes in the half year ended December 31, 2015. He says Phase I clinical trials for CHK1, its most advanced...

on 02/24/2016

2 min read